Pacific Edge Limited · NZX:PEB
Pacific Edge — Shareholder Meeting (February 2016)
12 slides from Pacific Edge's shareholder meeting presentation, Feb 26, 2016
Slide 1: Special Meeting and 2016 Progress Report
Special Mee*ng and 2016 Progress Report 26 February 2016 David Darling, CEO and Chris Swann, Chairman
Slide 2: Purpose of Special Meeting
PURPOSE OF SPECIAL MEETING To approve an increase in the total pool of directors’ fees from $198,000 to $275,000 • This will allow for payment of director’s fees to newly appointed, US-based, independent director, David Levison, of $77,000 (the amount of the increase). • There will be no increase in
Slide 3: David Levison
DAVID LEVISON David is an experienced and successful execu*ve, with highly relevant skills and an indepth knowledge and experience in the US healthcare market, which has been iden*fied as Pacific Edge’s primary growth opportunity • CEO and a Director of CardioDx, a specialist molecular diagnos*c compa
Slide 4: Resolution
RESOLUTION That pursuant to clause 25 of the Company's Cons*tu*on and NZX Lis*ng Rule 3.5.1 the maximum aggregate amount per annum payable by the Company to its Directors be increased to $275,000. The Directors and their associates are excluded from vo*ng on this resolu*on and from exercising any di
Slide 5: Proxies and Postal Votes
PROXIES AND POSTAL VOTES We have received the following valid votes and proxies: PROXIES AND POSTAL VOTES FOR AGAINST DISCRETIONARY VALID VOTES/ % OF TOTAL ISSUED PROXIES RECEIVED CAPITAL Approval for increase 128,779,392 27,394,223 520,439 156,694,054 41.61 % in total director’s fees 82.19 % 17.48
Slide 6: 2016 Progress Report
2016 PROGRESS REPORT Chief Execu@ve Officer, David Darling Pacific Edge February 2016 Special Mee*ng
Slide 7: Product Development
PRODUCT DEVELOPMENT Pacific Edge is the only cancer diagnos*cs company in the world to offer three proprietary molecular diagnos*c products for the detec*on and management of bladder cancer and designed to meet different clinical needs. • Cxbladder Detect: Ini*ally launched in New Zealand with US launc
Slide 8: USA Healthcare Market
USA HEALTHCARE MARKET EXPANDED US SALES • Achieved targeted sales force size with 18 sales execu*ves covering 19 targeted major FORCE metropolitan regions • Pacific Edge has iden*fied these regions as covering 60% of its poten*al market in the USA. LAUNCH OF NEW • Cxbladder Detect: In market since 201
Slide 9: Other Markets
OTHER MARKETS AUSTRALIA • February 2016: Announced new commercial partnership with Tolmar Australia Pty Limited, a specialised uro-oncology company which provides medicine and support to men with advanced prostate cancer • Tolmar will provide sales and marke*ng for Pacific Edge’s Cxbladder tests in A
Slide 10: Strategic Opportunities for Growth
STRATEGIC OPPORTUNITIES FOR GROWTH Targe*ng High Growth Over The Medium Term by Crea*ng More Products and Building Sales in an Increasing Number of Markets • Development of suite of Cxbladder products More Products • IP over other cancer expressions with opportunity to develop specific diagnos*c test
Slide 11: Pacific Edge websites and contact
www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com David Darling Chief Execu*ve Officer Pacific Edge Limited Tel: +64 3 479 5802 Mobile: +64 21 797981 Email: dave.darling@pelnz.com Pacific Edge February 2016 Special Mee*ng
Slide 12: Disclaimer
DISCLAIMER Informa<on The informa*on in this presenta*on is an overview and does not contain all informa*on necessary to make an investment decision. It is intended to cons*tute a summary of certain informa*on rela*ng to the performance of Pacific Edge Limited . The informa*on in this presenta*on is